
- /
- Supported exchanges
- / US
- / SVA.NASDAQ
Sinovac Biotech Ltd (SVA NASDAQ) stock market data APIs
Sinovac Biotech Ltd Financial Data Overview
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Sinovac Biotech Ltd data using free add-ons & libraries
Get Sinovac Biotech Ltd Fundamental Data
Sinovac Biotech Ltd Fundamental data includes:
- Net Revenue: 511 M
- EBITDA: 220 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-30
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sinovac Biotech Ltd News

Sinovac board urges shareholders to reject rival slate ahead of meeting
BEIJING - Sinovac Biotech Ltd. (NASDAQ:SVA), a vaccine manufacturer with a market capitalization of $39.56 million and currently trading at $0.12 per share, has called on shareholders to vote against ...


SINOVAC Board of Directors Prevails Against Advantech/Prime's Lawsuit in Hong Kong
Hong Kong Court denies Advantech/Prime’s petition for Interim Relief Clears another legal hurdle for distribution of the US$55.00 per common share special cash dividend declared by the current SINO...

What to watch next week: UK shop prices, US employment, Constellation Brands, M&S and Sainsbury's
While developments around US trade tariffs and conflict in the Middle East continue to dominate market focus, there are also key economic data releases and a number of companies reporting in the comin...

Seeking a Cure for Sickly Corporate Governance at SinoVac
Chinese SinoVac Biotech Ltd. (Nasdaq: SVA) shares have been frozen since 2019 amid shareholder disputes when market cap was about $500 million SinoVac developed a wildly successful Covid vaccine and h...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.